Scholarlink

Purpose of review <p>The purpose of the review is to integrate existing information about the immune pathogenesis and potential targets for therapy of primary biliary cholangitis (PBC). </p> Recent findings <p>Recent advancements in immunology have shed light on the roles of various factors (like CXCL10, CCR2/CCR5, and IL-12/23), the generation of autoantibodies (such as AMA), and the immune dysregulation involving various cell types, including B-cells, CD4+, CD8+, Th17, Treg, NK cells, and macrophages. Clinical trials involving biologics such as rituximab, belimumab, ustekinumab, abatacept, NI-0801, Cenicriviroc, Secukinumab, Ruxolitinib, Baricitinib, PD 1/PD L1 Pathway Blockade, CNP-104, and Mesenchymal stem cells (MSCs) have demonstrated a modest or short-term immunological and biochemical impact in early-stage or pilot studies, but no consistent and long-lasting clinical advantages have been shown, highlighting the intricate nature of immune modulation in PBC.</p> Summary <p>PBC is a complex autoimmune liver disease influenced by a mix of genetic, environmental, and immune factors. While traditional immunosuppressants haven’t shown much promise, researchers are exploring precision therapies that focus on B-cells, T-cells, cytokines, and co-stimulatory pathways. Early trials have shown that they are safe and can modulate the immune response, but the research needs larger, more detailed studies to really understand their effectiveness and tackle pressing clinical issues.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Primary Biliary Cholangitis: Immune Pathogenesis and Potential Targets for Therapy

  • 期刊论文

  • 发表日期：

    2026年5月20日

查看全文
  • Mohamed Alsenbesy

摘要

Purpose of review

The purpose of the review is to integrate existing information about the immune pathogenesis and potential targets for therapy of primary biliary cholangitis (PBC).

Recent findings

Recent advancements in immunology have shed light on the roles of various factors (like CXCL10, CCR2/CCR5, and IL-12/23), the generation of autoantibodies (such as AMA), and the immune dysregulation involving various cell types, including B-cells, CD4+, CD8+, Th17, Treg, NK cells, and macrophages. Clinical trials involving biologics such as rituximab, belimumab, ustekinumab, abatacept, NI-0801, Cenicriviroc, Secukinumab, Ruxolitinib, Baricitinib, PD 1/PD L1 Pathway Blockade, CNP-104, and Mesenchymal stem cells (MSCs) have demonstrated a modest or short-term immunological and biochemical impact in early-stage or pilot studies, but no consistent and long-lasting clinical advantages have been shown, highlighting the intricate nature of immune modulation in PBC.

Summary

PBC is a complex autoimmune liver disease influenced by a mix of genetic, environmental, and immune factors. While traditional immunosuppressants haven’t shown much promise, researchers are exploring precision therapies that focus on B-cells, T-cells, cytokines, and co-stimulatory pathways. Early trials have shown that they are safe and can modulate the immune response, but the research needs larger, more detailed studies to really understand their effectiveness and tackle pressing clinical issues.